Krystal Biotech Reports Positive Interim Results for CF Gene Therapy KB407
TL;DR Summary
Krystal Biotech announced positive interim results from its Phase 1 trial of KB407, a gene therapy for cystic fibrosis, confirming successful lung delivery and expression of wild-type CFTR protein across diverse patients, paving the way for a larger, repeat-dosing study expected to start in 2026.
- Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis Krystal Biotech, Inc
- Krystal Biotech says it can deliver native protein to cystic fibrosis patients Endpoints News
- Assessing Krystal Biotech (KRYS) Valuation As Investors Await CORAL-1 KB407 Interim Cystic Fibrosis Data simplywall.st
- Krystal Biotech confirms CFTR delivery in CF patients with KB407 By Investing.com Investing.com South Africa
- Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
8 min
vs 9 min read
Condensed
97%
1,736 → 45 words
Want the full story? Read the original article
Read on Krystal Biotech, Inc